It was previously demonstrated that SGLT2 inhibitors as additions to insulin in T1DM treatment showed a great decrease in glucose level, body weight, and insulin dosage (3, 40–42). This evidence concerns the gene SLC5A2 and type 1 diabetes mellitus.